| INTRODUCTION
Patent foramen ovale (PFO) is present in approximately 25% of the general population. It is more prevalent in patients with cryptogenic stroke (CS), and is considered to be a source of paradoxical embolism. 1, 2 Prevalence of PFO is 40-60% in patients with migraine with aura (MA) 3 , and MA is also more prevalent in patients with PFO; 15-50% compared to 4-5% in the general population. 4 Hypotheses are that micro emboli through a PFO can trigger migraine attacks, 5 and also that higher levels of vasoactive substances in the systemic circulation, normally degraded in the lungs, can trigger migraine attacks. 6 Endothelial dysfunction (ED) has been linked to both migraine and stroke. The main features of ED are impaired endothelium-dependent vasodilatation and endothelial activation, where release of cytokines and chemokines cause a pro-inflammatory and pro-thrombotic environment. ED can be assessed either by measuring changes in vascular tone in response to shear stress, using different techniques like flow-mediated dilatation (FMD) or peripheral arterial tonometry, 7 or analysing biomarkers of endothelial activation. ED is associated with development of atherosclerosis and future cardiovascular disease, 8 but might also be involved in migraine pathophysiology, both as a cause and a consequence of migraine attacks. 9 Several studies have shown increased levels of biomarkers associated with ED in patients with migraine, however, studies exploring vascular reactivity in migraneurs have shown conflicting results. 10 Still, ED remains as one of the hypotheses behind the increased risk for stroke and cardiovascular disease seen in patients with migraine. 11, 12 The effect of PFO closure on endothelial function has not previously been studied.
In the clinical setting, we frequently experience cases with onset, or worsening of MA, in relation to closure of a PFO, later followed by long-lasting improvement of migraine frequency. In the literature, PFO closure has been associated to a reduction in migraine days, 13, 14 although two randomized trials; MIST 15 and PRIMA 16 failed to reach their primary endpoint in reduction of overall migraine days. However, post hoc analyzes of the PRIMA trial showed reduction in migraine attacks preceded by aura. PFO closure has also been associated with initial worsening of migraine, 17 and Rigatelli et al showed that patients with post procedural attacks of MA where more likely to benefit from closure in regards to migraine improvement. 18 In this study, we aimed to investigate endothelial function in patients with CS and PFO, to explore whether it was altered after closure of the PFO, and to what extent that could be associated with any change in migraine frequency after PFO closure. PFO were included. They were followed at baseline (day before closure of PFO), day after PFO closure, and at 1 and 6 months after closure. To control for any improvement in endothelial function being an effect of time after the ischemic event, controls with CS, and PFO continuing on medical treatment only were included (N = 7). Controls were followed at the same intervals. The study was approved by the local ethics committee, and all patients gave their written, informed consent prior to their inclusion in the study.
| Data collection
As part of the diagnostic work-up after the index stroke, all patients were examined with MRI of the brain, imaging of the neck vessels, holter-ECG for detection of atrial fibrillation, transesophageal echocardiogram, and extensive laboratory tests including analyses of the most common coagulopathies. Medical data from index stroke were taken from patient records and patient history. Neurological examination was performed by study investigator at screening visit prior to inclusion. A previous diagnosis of migraine according to IHS criteria 19 and migraine frequency was assessed, using a questionnaire previously developed and validated by the headache research group at the Karolinska University Hospital, 20 and followed-up by clinical evaluation at baseline visit. A headache journal was used to evaluate migraine attacks at follow-up visits.
| Assessment of endothelial function
A finger plethysmograph, Endo-PAT 2000® (Itamar Medical) was used to assess endothelial function. EndoPat® measures pulse wave amplitude in the fingertip at baseline and as a response to shear stress. Changes in pulse wave amplitude are used to calculate a reactive hyperaemia index (RHI), or EndoPat®-score, corresponding to the peripheral endothelial function. A score <167 has been correlated to ED. 21 The patient's other arm serve as an internal control. The method has previously been described in detail. 22 It has been proven to have good reproducibility, 23 and is easy and convenient to use, as well as a user-independent method. Plasma and serum was withdrawn for analyses of biomarkers of endothelial function. Endothelin-1 (ET-1) was analyzed with ELISA using Kit
QuantiGlo® from R&D systems. Levels of hsCRP, von Willebrand Factor (vWF), and homocysteine (Hcy) were analyzed at the Karolinska University Laboratory using standardized methods. Blood samples were taken in the morning with patients fasting for a minimum of 4 h.
| Statistics
All data are presented as mean with standard deviation (SD) for 
| Background characteristics
In all, 26 individuals were followed according to protocol. One patient started as a control but after 6 months had a PFO closure, due to a recurrent ischemic event, and therefore continued in the closure arm.
All included patients, regardless of treatment allocation, had a nonlacunar stroke within the last months before inclusion, and diagnostic work-up did not reveal any source of large artery atherosclerosis, small vessel occlusion, or source of cardiac embolism other than PFO. One patient had a coagulopathy with positive lupus-antibodies as well as being heterozygous for Factor V Leiden. Details regarding MRI and echocardiography findings are seen in Table 1 . Mean time from stroke to baseline EndoPat evaluation was 5.2 month; SD 1.6; range 1.5-8.0.
All patients were on concomitant therapy with either an anti-platelet (n = 25) or anticoagulant medication (n = 1), and 85.6% of patients were treated with statins as part of standardized stroke care. There was an equal gender distribution with 50% females and 50% males, and mean age of patients was 45.4 years of age. Three patients (11.1%) had a history of previous cerebrovascular disease, and were on antiplatelet treatment at the time for index stroke. Another six patients (22.2%) had silent infarcts on imaging. The majority of the patients lacked cardiovascular risk factors and standard blood analyses were within normal range, including lipid profile. Background characteristics in the whole cohort and divided according to closure of PFO or controls are shown in Table 2 . Fifty percent of the patient had a history of migraine prior to the stroke, where the majority had MA (n = 11) (84.6%). Of the two patients with migraine without aura, one developed migraine attacks with aura after closure. All migraine patients were allocated among patients going through closure of the PFO, including the patient starting as a control. 
| EndoPat evaluation
Median RHI at baseline for all patients was 1.60 (IQR 1.41-2.00) (Fig. 1) . Control patients had a lower RHI compared to closure patients; There was no significant change in RHI in closure patients, either from baseline to post closure (P = 0.46), or from baseline and the first 6 month after closure of PFO (P = 0.66) (Fig. 2) . Neither controls had a significant change from baseline to day 1 (P = 0.23), or over the 6 month period (P = 0.32). When looking at migraine patients (n = 13) separately, there was no change over time, P = 0.87 (Fig. 2) . In patients with RHI at baseline indicating ED (n = 10), there was a non-significant trend to improved values over time (P = 0.08) (Fig. 2 ).
| Markers of endothelial dysfunction
Median plasma level of ET-1 at baseline (n = 26) was 2. 
| Migraine frequency
Baseline migraine frequency ranged from several times per week to 2-3 times per year, but 53.8% (n = 7) of the migraine patients had less than one migraine attack per month. After closure of their PFO, three patients reported an increase of migraine attacks, with aura daily or several days per week, the worst period being the first month after closure. After the 6 month period, three patients had less migraine attacks than before, three patients had more, and seven patients had no change in migraine frequency. At a second follow-up (mean 43.4
month; SD ± 13.6); 69% (n = 9) of the patients with migraine reported of less frequent migraine attacks. Six patients had none or less than one migraine attack per year (Fig. 3 ). 
| Assessment of endothelial function
ED develops in the presence of cardiovascular risk factors and has a key role in the development of future atherosclerosis. 24 Analyzing peripheral endothelial function with EndoPat® has previously been shown to identify high risk patients with coronary artery disease (CAD) and to predict future cardiovascular events in patients with stable CAD. [25] [26] [27] EndoPat® has also been investigated in patients with acute ischemic stroke (assessed within 5 days after stroke), showing impaired endothelial function compared to healthy controls in stroke of different etiology, including CS. 28 In our patients, baseline evaluation was done in the convalescent phase after stroke. Median RHI at baseline was 1.60 (IQR 1.41-2.00). This is in line with previous data in patients with ischemic stroke in the acute phase (mean RHI 1.8; SD ± 0.3) 28 and in women with ischemic heart disease (median RHI 1.57 (IQR 1.42-1.76), and median RHI 1.58 (IQR 1.41-1.78)). 29 In comparison, previously published data on healthy men showed mean RHI 2.2; SD ± 0.6 30 and in healthy controls mean RHI 2.2; SD ± 0.4. 28 Sunbul et al, previously investigated ED using FMD, in patients with CS with or without PFO and compared to healthy controls. 31 They found that ED was an independent risk factor for stroke regardless of the presence of a PFO, and that endothelial function was impaired in stroke-patients with PFO compared to non-stroke patients with PFO.
However, in the study by with Sunbul et al, mean age was older, and a large part of the patients had hypertension or diabetes. In comparison, our patients were younger and the majority was lacking cardiovascular risk factors. Our patients were also on concomitant therapy with anti-platelet (96.1%) and statin treatment (85.6%), which both are known to improve endothelial function. 32, 33 The selected biomarkers analyzed in this study, ET-1, vWF, Hcy, and hsCRP, have all previously been associated with ED/-activation and inflammation, also in relation to stroke and cardiovascular disease. [34] [35] [36] [37] In patients with CS and PFO, the best treatment regime to prevent recurrent stroke is still debated. Three randomized trials have failed to
show a significant benefit of closure over medical treatment. [40] [41] [42] EndoPat has previously been used to predict future cardiovascular events in patients with CAD, and whether ED can be a predictor of patients with PFO of higher risk for recurrent stroke should be addressed in future studies.
| Change in endothelial function after PFO closure
Apart from enabling paradoxical embolism, a PFO with a right-to-left shunt at rest or Valsalva, might also result in increased plasma levels of vasoactive substances, normally degraded in the lung. This may have a systemic effect and increase the risk for cerebrovascular injury. 43 Also, shunting of micro bubbles through a PFO has been shown to directly impair endothelial function, when assessed with FMD. 44 In our study, 
| Change in migraine after closure
As previously mentioned migraine frequency can change after PFO closure; with both relieve from migraine attacks and initial worsening.
Our data show similar trends, where a subgroup of patients (n = 3)
reported a temporary increase in migraine attacks with aura after
closure. There was no visible trend regarding change in endothelial 
| CONCLUSION
In our study of patients with CS and PFO, the endothelial function was unaffected by PFO closure. However, despite the lack of cardiovascular risk factors and in the presence of anti-thrombotic and statin treatment, the majority of patients had an impaired endothelial function. Whether assessment of endothelial function can add predictive value to identify PFO at a higher risk of recurrent stroke warrants further investigations.
ACKNOWLEDGMENT
This study was partly funded by a scholarship from the Swedish Stroke Society.
